Search

The utilization of CO2 from flue gas as a C1 feedstock for the catalytic synthesis of high-valued oxazolidinones is highly important but challenging due to the low CO2 concentration and high activation barrier for CO2. Herein, we present an efficient and stable CuI-anchored porous covalent organic framework CuI@TpBD-COF for effective catalysis of the carboxylic cyclization reaction between propargylic amines and CO2 to produce various functionalized oxazolidinone derivatives under mild conditions. The yield is up to 99% and the turnover frequency (TOF) reaches a record value of 1058 h−1, significantly surpassing almost all previously reported metal heterogeneous catalysts. Furthermore, CuI@TpBD-COF also demonstrates efficient catalytic activity when simulated flue gas is used as the source of CO2. This work provides new guidance for the design of more efficient and eco-friendly noble-metal-free catalytic materials to drive the ideal CO2 chemical fixation process. [ABSTRACT FROM AUTHOR]

Background Cardiac involvement is a serious complication of idiopathic inflammatory myopathy (IIM). GDF-15 can predict the risk and the prognosis of cardiovascular disease, but its value is unclear in IIM. Objective To investigate the diagnostic value of GDF-15 for myocardial involvement in IIM. Methods A total of 77 IIM patients from May 2018 to August 2020 were included in this retrospective study. Of these, 43 patients underwent cardiac magnetic resonance (CMR) examination. There were 33 SLE patients and 16 healthy people were used as the control group. The concentration of GDF-15 of these groups was measured by ELISA. Results There were significant differences in GDF-15 levels in patients with IIM, SLE and healthy controls (H = 45.291, P <0.001). GDF-15 levels were statistically significant different between IIM patients with the myocardial injury [1484.88(809.07 2835.50) pg/ml] and without myocardial injury [593.26(418.61 784.59) pg/ml, P  =0.001]. After adjusted for age, renal function, the risk of myocardial injury in IIM patients increased an average of 0.3% by per increased unit of GDF-15 (odds ratio=1.003, 95% CI: 1.000, 1.007). The level of GDF-15 was positively correlated with extra-cellular volume (ECV) (r s = 0.348, P  =0.028). GDF-15 ≥ 929.505 pg/ml (area under the curve=0.856, 95% CI: 0.744, 0.968) predicted myocardial injury in IIM with a sensitivity of 0.75 and specificity of 0.90. Conclusion GDF-15 could serve as a potential biomarker to predict myocardial injury in IIM patients. [ABSTRACT FROM AUTHOR]

• IIM patients with myocardial injury had significantly higher YKL-40 concentration than non– myocardial injury. • serum YKL-40 was an independent risk factor for myocardial involvement in IIM. • In this retrospective study, we illustrate the potential of YKL-40 as reliable diagnostic biomarkers for predicting myocardial injury in IIM. To investigate the diagnostic value of serum chitinase-3-like-1 protein (YKL-40) levels for myocardial involvement in idiopathic inflammatory myopathies (IIM). A total of 74 patients with definite IIM who visited Jiangsu Province People's Hospital between May 2018 and January 2022 were enrolled in this retrospective study. Baseline clinical evaluation, laboratory index, electrocardiogram (ECG), echocardiography (ECHO) and cardiac magnetic resonance (CMR) parameters were collected. Serum YKL-40 of all participants was determined by ELISA. Receiver-operating characteristic (ROC) curve was used to assess the diagnostic value of YKL-40 in assessing myocardial involvement in IIM patients. 1. YKL-40 concentration was significantly higher in IIM patients with myocardial injury than without myocardial injury.2. Multivariate logistic regression analysis demonstrated that serum YKL-40 was an independent risk factor for myocardial involvement in IIM.3. YKL-40 > 66.4 ng/ml (AUC = 0.85, 95 % CI 0.75–0.95) predicted myocardial injury in IIM with a sensitivity of 0.75 and specificity of 0.95. Serum YKL-40 could serve as a potential biomarker to predict myocardial injury in IIM patients. [ABSTRACT FROM AUTHOR]